Tezepelumab granted Priority Review by U.S. FDA
The Pharma Data
JULY 8, 2021
Many patients with severe asthma have an inadequate response to currently available biologics and oral corticosteroids and thus fail to achieve asthma control.(2,6,9) Amgen (NASDAQ:AMGN) announced that the U.S. Tezepelumab is being developed by Amgen in collaboration with AstraZeneca. Reese, M.D., About Severe Asthma.
52 
Let's personalize your content